ClinicalTrials.gg

Program

mocravimod

Also written as “KRP-203”, “Study Part 1: KRP203” and “Study Part 2: KRP203 lower dose”.

Its studies are mostly in Leukemia, Myeloid, Acute · Hematologic Neoplasms · Colitis, Ulcerative · Lupus Erythematosus, Cutaneous, led by 2 companies.

Furthest: phase 3, since Feb 10, 20115 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis30 open or runningphase 2since Feb 10, 2011Feb 10, 2011none ahead
Priothera SAS21 open or runningphase 3since Jun 17, 2022Jun 17, 2022May 2027phase 3 · NCT05429632

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2011First study: phase 2 study in Lupus Erythematosus, CutaneousNew to NovartisNovartis · NCT01294774 · 10 enrolled · Germany, Greece, Italy
  2. May 12, 2011Phase 2 study in Colitis, UlcerativeNovartis · NCT01375179 · 27 enrolled · Belgium, Germany, Hungary and more
  3. Apr 9, 2013Phase 1 study in Hematologic NeoplasmsNovartis · NCT01830010 · 23 enrolled · France, Germany, Switzerland
  4. Jun 17, 2022Priothera SAS's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Priothera SASPriothera SAS · NCT05429632 · 366 planned · United States, Argentina, Brazil and more
  5. Oct 7, 2026Phase 1 study in Healthy VollunteerPriothera SAS · NCT07937046 · 64 enrolled

Ahead

  1. May 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcutePriothera SAS · NCT05429632

TargetBeta

“The hydrochloride salt form of mocravimod, a sphingosine 1-phosphate (S1P) receptor agonist, ”NCIt, by rule
“Sphingosine 1-phosphate receptor Edg-1 agonist”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07937046Healthy Vollunteer1CompletedPriothera SASMay 16, 201164
NCT05429632Leukemia, Myeloid, Acute · United States, Argentina, Brazil and more3RecruitingPriothera SASMay 2027366
NCT01830010Hematologic Neoplasms · France, Germany, Switzerland1CompletedNovartisAug 21, 201823
NCT01375179Colitis, Ulcerative · Belgium, Germany, Hungary and more2TerminatedNovartisMay 201227
NCT01294774Lupus Erythematosus, Cutaneous · Germany, Greece, Italy2CompletedNovartisOct 201210

How it is read

Names in the registry

  • “KRP-203”, 1 entry
  • “mocravimod”, 1 entry
  • “Study Part 1: KRP203”, 1 entry
  • “Study Part 2: KRP203 lower dose”, 1 entry
  • “Study Part 2: KRP203 higher dose”, 1 entry

Codes read as this program: KRP203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.